Nasdaq
$2.08▼ 1.19%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $242.4MShares out 1.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 9.28Pre-market26.09.28 21:108-KKey event#●●●#●●●
FATE THERAPEUTICS INCBullish
Fate Therapeutics has been awarded a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the Phase 2 RECLAIM-LN clinical trial of its FT819 therapy for lupus nephritis. The funding will be utilized to advance the clinical development of this off-the-shelf CAR T-cell candidate and expand patient access.…more
$2.08-1.19%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.13Pre-market26.08.13 21:3410-QEarnings
FATE THERAPEUTICS INC
Fate Therapeutics filed its Form 10-Q for the quarter ended June 30, 2026, disclosing its financial condition and operational results. As of August 6, 2026, the company had 119,820,514 shares of common stock issued and outstanding, with management certifying that the report fairly presents the company's financial position in accordance with accounting standards.…more
$2.08-1.19%vs prev closeView filingShare - 8.13Pre-market26.08.13 21:318-KKey event
FATE THERAPEUTICS INC
Fate Therapeutics reported Q2 2026 revenue of $2.1 million and a net loss of $30.2 million ($0.25 per share). The company successfully dosed the first patient in the Phase 2 trial for FT819 in lupus nephritis and received FDA clearance for the FT839 Phase 1/2 trial. With $153.8 million in cash and investments, the company maintains an operational runway into 2028.…more
$2.08-1.19%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.12Pre-market26.10.12 20:00#●●●#●●●
Fate Therapeutics Appoints New Executive to Lead Commercialization Strategy…more
Fate Therapeutics has appointed Jamie Harrell as Senior Vice President to lead the commercialization strategy for its CAR T-cell therapy pipeline. This appointment aims to strengthen the company's leadership as it transitions from clinical development toward commercialization.…more
$2.08-1.19%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.2Pre-market26.10.02 20:00
●●●●●●●● ●●●●● ●●●●●●
Fate Therapeutics announced the grant of stock options and restricted stock units (RSUs) to newly hired employees as an inducement for their employment. This move is a standard administrative procedure under Nasdaq rules and does not impact the company's financial performance.…more
$2.08-1.19%vs prev close - 10.1Pre-market26.10.01 20:00
●●●●●●●● ●●●●● ●●●●●●
Fate Therapeutics announced its participation in upcoming healthcare investor conferences during the fourth quarter of 2026. This is a routine corporate update and does not provide new material financial information.…more
$2.08-1.19%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report